Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other financing activities (2019 - 2025)

Biodesix's Other financing activities history spans 7 years, with the latest figure at -$847000.0 for Q4 2025.

  • For Q4 2025, Other financing activities fell 364.69% year-over-year to -$847000.0; the TTM value through Dec 2025 reached -$817000.0, down 1956.82%, while the annual FY2025 figure was -$817000.0, 1956.82% down from the prior year.
  • Other financing activities reached -$847000.0 in Q4 2025 per BDSX's latest filing, down from $3000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $320000.0 in Q4 2024 to a low of -$847000.0 in Q4 2025.
  • Average Other financing activities over 5 years is -$41500.0, with a median of -$9000.0 recorded in 2022.
  • Peak YoY movement for Other financing activities: surged 1600.0% in 2021, then crashed 1000.0% in 2022.
  • A 5-year view of Other financing activities shows it stood at $68000.0 in 2021, then crashed by 113.24% to -$9000.0 in 2022, then tumbled by 577.78% to -$61000.0 in 2023, then surged by 624.59% to $320000.0 in 2024, then crashed by 364.69% to -$847000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Other financing activities are -$847000.0 (Q4 2025), $3000.0 (Q3 2025), and $225000.0 (Q2 2025).